Open Orphan - Contract for COVID-19 Vaccine Trial
ORPH Tue, 28 Jul 2020, 11:45am BST
Open Orphan was founded in 2017, with the goal of becoming Europe’s leading rare disease and orphan drug focused pharma services company by a management team with extensive industry and financial expertise.
Industry: Health Care
Contact: +353 (01) 6440007
Dublin 2, Ireland
Cathal Friel, Executive Chairman, Open Orphan announces a new contract with Codagenix to conduct a first in human (Phase I) trial evaluating safety and immunogenicity of a single-dose, intranasal COVID-19 vaccine candidate in 48 healthy young adult volunteers.